Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. [electronic resource]
Producer: 20120330Description: e64-8 p. digitalISSN:- 1527-7755
- Adolescent
- Adult
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Benzenesulfonates -- administration & dosage
- Bevacizumab
- Child
- Child, Preschool
- Drug Synergism
- Erlotinib Hydrochloride
- Female
- Humans
- Indoles -- administration & dosage
- Male
- Molecular Targeted Therapy -- methods
- Neurofibromatosis 2 -- drug therapy
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Pyridines -- administration & dosage
- Pyrroles -- administration & dosage
- Quinazolines -- administration & dosage
- Sirolimus -- administration & dosage
- Sorafenib
- Sunitinib
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Treatment Outcome
- Valproic Acid -- administration & dosage
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.